Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer.
Xiao L, Parolia A, Qiao Y, Bawa P, Eyunni S, Mannan R, Carson SE, Chang Y, Wang X, Zhang Y, Vo JN, Kregel S, Simko SA, Delekta AD, Jaber M, Zheng H, Apel IJ, McMurry L, Su F, Wang R, Zelenka-Wang S, Sasmal S, Khare L, Mukherjee S, Abbineni C, Aithal K, Bhakta MS, Ghurye J, Cao X, Navone NM, Nesvizhskii AI, Mehra R, Vaishampayan U, Blanchette M, Wang Y, Samajdar S, Ramachandra M, Chinnaiyan AM.
Xiao L, et al.
Nature. 2022 Jan;601(7893):434-439. doi: 10.1038/s41586-021-04246-z. Epub 2021 Dec 22.
Nature. 2022.
PMID: 34937944
Free PMC article.
Here we developed a proteolysis-targeting chimera (PROTAC) degrader of the SWI/SNF ATPase subunits, SMARCA2 and SMARCA4, called AU-15330. Androgen receptor (AR)(+) forkhead box A1 (FOXA1)(+) prostate cancer cells are exquisitely sensitive to dual SMARCA2 and SMARCA4 …
Here we developed a proteolysis-targeting chimera (PROTAC) degrader of the SWI/SNF ATPase subunits, SMARCA2 and SMARCA4, called AU-15 …